Chitosan improves insulin sensitivity as determined by the euglycemic-hyperinsulinemic clamp technique in obese subjects

Nutrition Research

Volumn 30, Issue 6, 2010, Pages 392-395

  Hernández González, Sandra O ^a   González Ortiz, Manuel ^a,b   Martínez Abundis, Esperanza ^a,b   Robles Cervantes, José A ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSITY OF GUADALAJARA   (Mexico)

Author keywords

Chitosan; Euglycemic hyperinsulinemic clamp technique; Insulin sensitivity; Lipids; Obese patients; Obesity; Triglycerides

Indexed keywords

CHITOSAN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; BLOOD; BODY WEIGHT; DRUG EFFECTS; MIDDLE AGED; PROCEDURES;

ADULT; BODY MASS INDEX; BODY WEIGHT; CHITOSAN; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 77954894220     PISSN: 02715317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nutres.2010.06.005     Document Type: Article

References (15)

1. Guh D.P., Zhang W., Bansback N., Amarsi Z., Birmingham C.L., Anis A.H. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009, 9:88.
2. Rucker D., Padwal R., Li S.K., Curioni C., Lau D.C. Long-term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007, 335:1194-1199.
3. Kurita K. Chitin and chitosan: functional biopolymers from marine crustaceans. Mar Biotechnol (NY) 2006, 8:203-226.
4. Singla A.K., Chawla M. Chitosan: some pharmaceutical and biological aspects-an update. J Pharm Pharmacol 2001, 53:1047-1067.
5. Tai T.S., Sheu W.H.H., Lee W.J., Yao H.T., Chiang M.T. Effect of chitosan on plasma lipoprotein concentrations in type 2 diabetic subjects with hypercholesterolemia. Diabetes Care 2000, 23:1703-1704.
6. Jull A.B., Ni Mhurchu C., Bennett D.A., Dunshea-Mooij C.A., Rodgers A. Chitosan for overweight or obesity. Cochrane Database Syst Rev 2008, 3:CD003892.
7. DeFronzo R.A., Tobin J.D., Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979, 237:E214-E223.
8. Jacques-Camarena O., González-Ortiz M., Martínez-Abundis E., López-Madrueño J.F.P., Medina-Santillán R. Effect of vanadium on insulin sensitivity in patients with impaired glucose tolerance. Ann Nutr Metab 2008, 53:195-198.
9. Jeyaseelan L., Rao P. Methods of determining sample size in clinical trials. Indian Pediatr 1989, 26:115-121.
10. González-Ortiz M., Martínez-Abundis E., Jacques-Camarena O., Hernández-González S.O., Valera-González I.G., Ramos-Zavala M.G. Prevalence of metabolic syndrome in adults with excess of adiposity: comparison of the Adult Treatment Panel III criteria with the International Diabetes Federation definition. Acta Diabetol 2006, 43:84-86.
11. Forst T., Hohberg C., Pfützner A. Cardiovascular effects of disturbed insulin activity in metabolic syndrome and in type 2 diabetic patients. Horm Metab Res 2009, 41:123-131.
12. Hayashi K., Ito M. Antidiabetic action of low molecular weight chitosan in genetically obese diabetic KK-Ay mice. Biol Pharm Bull 2002, 25:188-192.
13. Lee H.W., Park Y.S., Chol J.W., Yi S.Y., Shin W.S. Antidiabetic effects of chitosan oligosaccharides in neonatal streptozotocin-induced noninsulin-dependent diabetes mellitus in rats. Biol Pharm Bull 2003, 26:1100-1103.
14. Pittler M.H., Ernst E. Dietary supplements for body-weight reduction: a systematic review. Am J Clin Nutr 2004, 79:529-536.
15. Bougoulia M., Triantos A., Koliakos G. Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women. Hormone 2006, 5:259-269.